Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


30,00 € / $42.00 / £23.00

Get Access to Full Text

Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target

1, 2 / Giuseppe Marano2 / Elia M. Biganzoli2 / Patrizia Boracchi2 / Angelo S. Bongo1

1SCDO, Cardiologia 2, Ospedale Maggiore, Novara, Italy

2Sezione Statistica Medica e Biometria, Dipartimento di Medicina del Lavoro, Università degli Studi, Milan, Italy

Corresponding author: Simona Ferraro, SCDO Cardiologia 2, Ospedale Maggiore, Corso Mazzini 18, Novara 28100, Italy Phone: +393471598351, Fax: +390250320866

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 9, Pages 1397–1404, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2011.607, May 2011

Publication History

Published Online:


Background: Cystatin C (CC) has been proposed to play a role in atherosclerosis. We aimed to review the prognostic value of CC serum/plasma levels in patients with acute coronary syndromes (ACS).

Methods: Fifteen observational longitudinal studies were selected by Medline.

Results: Increased CC over threshold values ranging from 0.93 to 1.3 mg/L were prognostic for death (hazard ratio; HR: 2.04–3.6) and for the occurrence of any fatal and non-fatal cardiovascular events (HR: 1.7–9.6) for patients with either ACS only or coronary heart disease and prevalent ACS. Only one study showed an increased risk for future myocardial infarction (MI) in patients with marker levels higher than 1.0 mg/L. Three studies reported the risk associated with a change of one unit of CC for long-term death (HR ranging from 1.9 to 6.3) and for the composite end point of 1 year MI and death (HR 2.15). Some studies showed the additional prognostic value contributed from CC measurements to other markers and to conventional risk scores.

Conclusion: Despite low to moderate evidence, there is a general agreement on the significant prognostic value of CC in ACS that might encourage further research focused on risk assessment for patients with MI.

Keywords: acute coronary syndromes; atherosclerosis; inflammatory biomarkers; prognosis; risk factor

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Supriya Joshi and Adie Viljoen
Current Opinion in Cardiology, 2015, Page 1
J.-b. Zhang, L.-f. Liu, Z.-g. Li, H.-r. Sun, and X.-h. Ju
American Journal of Hypertension, 2015, Volume 28, Number 6, Page 739
Jin-Biao Zhang, Xiao-Hua Jü, Jing Wang, Hai-Rong Sun, and Fang Li
Journal of Clinical Neuroscience, 2014, Volume 21, Number 2, Page 268
Meng Zhang, Shu-Hong Fu, Hua Cui, Bing-Po Zhu, Lin Liu, and De-Long Wang
Aging Clinical and Experimental Research, 2014, Volume 26, Number 2, Page 193
Min Ji Shin, Sang Heon Song, Ihm Soo Kwak, Soo Bong Lee, Dong Won Lee, Eun Young Seong, Il Young Kim, Harin Rhee, and Naria Lee
Clinical and Experimental Nephrology, 2012, Volume 16, Number 3, Page 456

Comments (0)

Please log in or register to comment.